Going Public In Mid-Pandemic

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Public health crises trigger challenges all down the line of medical practice, especially in the advancement of new medicines for conditions unrelated to a pandemic disease. Companies developing new therapeutics for such conditions may be stalled in a windless sea, while the interest of investors and the medical community turns elsewhere.